Development of Targeted Therapies for Rhabdoid Tumors Based on the Functions of INI1/hSNF5 Tumor Suppressor

  • Ganjam V. Kalpana
  • Melissa E. Smith


Rhabdoid tumors (RTs) are rare, but highly aggressive and mostly incurable ­pediatric malignancies (Strother 2005; Biegel 2006). RTs occur in children younger than 5 years of age and the peak incidence is between birth and 3 years of age (Biegel 2006). RTs were originally described in kidneys and termed Malignant Rhabdoid Tumors (MRT), and were subsequently found in the central nervous system (Atypical Teratoid and Rhabdoid Tumors, AT/RT), and soft tissues (extra-renal Rhabdoid Tumors) (Biegel 2006). Irrespective of their location, all RTs are characterized by the presence of sheets or nests of rhabdoid cells. Recent molecular genetic studies have established that RTs are distinguished from other tumors by the presence of recurrent biallelic deletions and/or mutations in the INI1/hSNF5 gene, located at chromosome 22q11.2, providing a definitive diagnostic criteria (Versteege et al. 1998; Biegel 1999; Biegel et al. 1999; Sevenet et al. 1999). Current therapeutic regimens for RT involve empirically selected combinations of chemotherapeutic agents that are highly toxic and rarely curative, as such, the survival rate for children with RTs remains poor (Packer et al. 2002; Reddy 2005; Strother 2005; Biegel 2006; Yamamoto et al. 2006). Thus, there is a dire need to develop novel therapeutic strategies for RTs, preferably based on the understanding of the molecular factors responsible for the genesis, growth, and survival of these tumors. In the following sections, we will describe features of RTs, current therapeutic practices, the molecular basis of rhabdoid tumorigenesis, and development of potential targeted therapies based on these understandings.


Rhabdoid Tumor Gene Expression Profile Analysis Malignant Rhabdoid Tumor Choroid Plexus Carcinoma Rhabdoid Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We apologize to all investigators whose work was not included in this article due to space limitation. Work in our laboratory is supported by grants from American Cancer Society, Children’s Tumor foundation, Mark Trauner faculty scholar and Irma T. Hirschl awards.


  1. Alarcon-Vargas, D., Zhang, Z., Agarwal, B., Challagulla, K., Mani, S., and Kalpana, G.V. 2006. Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene 25: 722–734.PubMedGoogle Scholar
  2. Albanese, P., Belin, M.F., and Delattre, O. 2006. The tumour suppressor hSNF5/INI1 controls the differentiation potential of malignant rhabdoid cells. Eur J Cancer 42: 2326–2334.PubMedGoogle Scholar
  3. Beckwith, J.B., and Palmer, N.F. 1978. Histopathology and prognosis of Wilms tumors: results from the First National Wilms’ Tumor Study. Cancer 41: 1937–1948.PubMedGoogle Scholar
  4. Bednarek, A., Shilkaitis, A., Green, A., Lubet, R., Kelloff, G., Christov, K., and Aldaz, C.M. 1999. Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumors. Carcinogenesis 20: 879–883.PubMedGoogle Scholar
  5. Betz, B.L., Strobeck, M.W., Reisman, D.N., Knudsen, E.S., and Weissman, B.E. 2002. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 21: 5193–5203.PubMedGoogle Scholar
  6. Biegel, J.A. 1999. Cytogenetics and molecular genetics of childhood brain tumors. Neuro Oncol 1: 139–151.PubMedGoogle Scholar
  7. Biegel, J.A. 2006. Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 20: E11.PubMedGoogle Scholar
  8. Biegel, J.A., Kalpana, G., Knudsen, E.S., Packer, R.J., Roberts, C.W., Thiele, C.J., Weissman, B., and Smith, M. 2002. The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 62: 323–328.PubMedGoogle Scholar
  9. Biegel, J.A., Zhou, J.Y., Rorke, L.B., Stenstrom, C., Wainwright, L.M., and Fogelgren, B. 1999. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59: 74–79.PubMedGoogle Scholar
  10. Blaney, S., Berg, S.L., Pratt, C., Weitman, S., Sullivan, J., Luchtman-Jones, L., and Bernstein, M. 2001. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 7: 32–37.PubMedGoogle Scholar
  11. Bonanni, B., Lazzeroni, M., and Veronesi, U. 2007. Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther 7: 423–432.PubMedGoogle Scholar
  12. Bowman, R., Clarke, B., Duhig, E., Larsen, J., and Fong, K. 2002. Re: Effects of N-(4-hydroxy-phenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 94: 949–950; author reply 950–941PubMedGoogle Scholar
  13. Bruch, L.A., Hill, D.A., Cai, D.X., Levy, B.K., Dehner, L.P., and Perry, A. 2001. A role for fluorescence in situ hybridization detection of chromosome 22q dosage in distinguishing atypical teratoid/rhabdoid tumors from medulloblastoma/central primitive neuroectodermal tumors. Hum Pathol 32: 156–162.PubMedGoogle Scholar
  14. Byrd, J.C., Lin, T.S., Dalton, J.T., Wu, D., Phelps, M.A., Fischer, B., Moran, M., Blum, K.A., Rovin, B., Brooker-McEldowney, M., et al. 2007. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109: 399–404.PubMedGoogle Scholar
  15. Cappellini, A., Tabellini, G., Zweyer, M., Bortul, R., Tazzari, P.L., Billi, A.M., Fala, F., Cocco, L., and Martelli, A.M. 2003. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression. Leukemia 17: 2157–2167.PubMedGoogle Scholar
  16. Caramel, J., Medjkane, S., Quignon, F., and Delattre, O. 2007. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors. Oncogene 27(14): 2035–2044.PubMedGoogle Scholar
  17. Chai, J., Charboneau, A.L., Betz, B.L., and Weissman, B.E. 2005. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res 65: 10192–10198.PubMedGoogle Scholar
  18. Chai, J., Lu, X., Godfrey, V., Fletcher, C., Roberts, C.W., Van Dyke, T., and Weissman, B.E. 2007. Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation. Cancer Res 67: 3002–3009.PubMedGoogle Scholar
  19. Chao, S.H., and Price, D.H. 2001. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276: 31793–31799.PubMedGoogle Scholar
  20. Chen, M.L., McComb, J.G., and Krieger, M.D. 2005. Atypical teratoid/rhabdoid tumors of the central nervous system: management and outcomes. Neurosurg Focus 18: E8.PubMedGoogle Scholar
  21. Cheng, S.-W.G., Davies, K.P., Yung, E., Beltran, R.J., Yu, J., and Kalpana, G.V. 1999. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22: 102–105.PubMedGoogle Scholar
  22. Christine Pratt, M.A., Niu, M., and White, D. 2003. Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids. J Cell Biochem 90: 692–708.Google Scholar
  23. Christov, K., Ikui, A., Shilkaitis, A., Green, A., Yao, R., You, M., Grubbs, C., Steele, V., Lubet, R., and Weinstein, I.B. 2003. Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors. Breast Cancer Res Treat 77: 253–264.PubMedGoogle Scholar
  24. de Azevedo, W.F. Jr., Canduri, F., and da Silveira, N.J. 2002. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 293: 566–571.PubMedGoogle Scholar
  25. Decatris, M., Santhanam, S., and O’Byrne, K. 2002. Potential of interferon-alpha in solid tumours: part 1. BioDrugs 16: 261–281.PubMedGoogle Scholar
  26. Delia, D., Aiello, A., Formelli, F., Fontanella, E., Costa, A., Miyashita, T., Reed, J.C., and Pierotti, M.A. 1995. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood 85: 359–367.PubMedGoogle Scholar
  27. DiPietrantonio, A.M., Hsieh, T.C., Olson, S.C., and Wu, J.M. 1998. Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer 78: 53–61.PubMedGoogle Scholar
  28. Donner, L.R., Wainwright, L.M., Zhang, F., and Biegel, J.A. 2007. Mutation of the INI1 gene in composite rhabdoid tumor of the endometrium. Hum Pathol 38: 935–939.PubMedGoogle Scholar
  29. Dragnev, K.H., Pitha-Rowe, I., Ma, Y., Petty, W.J., Sekula, D., Murphy, B., Rendi, M., Suh, N., Desai, N.B., Sporn, M.B., et al. 2004. Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 10: 2570–2577.PubMedGoogle Scholar
  30. Eckerdt, F., Yuan, J., and Strebhardt, K. 2005. Polo-like kinases and oncogenesis. Oncogene 24: 267–276.PubMedGoogle Scholar
  31. Ewen, M.E., and Lamb, J. 2004. The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 10: 158–162.PubMedGoogle Scholar
  32. Fenton, L.Z., and Foreman, N.K. 2003. Atypical teratoid/rhabdoid tumor of the central nervous system in children: an atypical series and review. Pediatr Radiol 33: 554–558.PubMedGoogle Scholar
  33. Fontana, J.A., and Rishi, A.K. 2002. Classical and novel retinoids: their targets in cancer therapy. Leukemia 16: 463–472.PubMedGoogle Scholar
  34. Formelli, F., Camerini, T., Cavadini, E., Appierto, V., Villani, M.G., Costa, A., De Palo, G., Di Mauro, M.G., and Veronesi, U. 2003. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome. Cancer Epidemiol Biomarkers Prev 12: 34–41.PubMedGoogle Scholar
  35. Fouladi, M., Blaney, S.M., Poussaint, T.Y., Freeman, B.B., 3rd, McLendon, R., Fuller, C., Adesina, A.M., Hancock, M.L., Danks, M.K., Stewart, C., et al. 2006. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 107: 2291–2297.PubMedGoogle Scholar
  36. Fu, M., Wang, C., Li, Z., Sakamaki, T., and Pestell, R.G. 2004. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145: 5439–5447.PubMedGoogle Scholar
  37. Fujisawa, H., Misaki, K., Takabatake, Y., Hasegawa, M., and Yamashita, J. 2005. Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation. J Neurooncol 73: 117–124.PubMedGoogle Scholar
  38. Garaventa, A., Luksch, R., Lo Piccolo, M.S., Cavadini, E., Montaldo, P.G., Pizzitola, M.R., Boni, L., Ponzoni, M., Decensi, A., De Bernardi, B., et al. 2003. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032–2039.PubMedGoogle Scholar
  39. Graham, C., Tucker, C., Creech, J., Favours, E., Billups, C.A., Liu, T., Fouladi, M., Freeman, B.B., 3rd, Stewart, C.F., and Houghton, P.J. 2006. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res 12: 223–234.PubMedGoogle Scholar
  40. Gresh, L., Bourachot, B., Reimann, A., Guigas, B., Fiette, L., Garbay, S., Muchardt, C., Hue, L., Pontoglio, M., Yaniv, M., et al. 2005. The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation. EMBO J 24: 3313–3324.PubMedGoogle Scholar
  41. Guan, R., Tapang, P., Leverson, J.D., Albert, D., Giranda, V.L., and Luo, Y. 2005. Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65: 2698–2704.PubMedGoogle Scholar
  42. Guidi, C.J., Sands, A.T., Zambrowicz, B.P., Turner, T.K., Demers, D.A., Webster, W., Smith, T.W., Imbalzano, A.N., and Jones, S.N. 2001. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 21: 3598–3603.PubMedGoogle Scholar
  43. Gururangan, S., Bowman, L.C., Parham, D.M., Wilimas, J.A., Rao, B., Pratt, C.B., and Douglass, E.C. 1993. Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide. Cancer 71: 2653–2659.PubMedGoogle Scholar
  44. Hail, N., Jr., Kim, H.J., and Lotan, R. 2006. Mechanisms of fenretinide-induced apoptosis. Apoptosis 11: 1677–1694.PubMedGoogle Scholar
  45. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell 100: 57–70.PubMedGoogle Scholar
  46. Hauser, P., Slowik, F., Bognar, L., Babosa, M., Fazekas, I., and Schuler, D. 2001. Atypical teratoid/rhabdoid tumor or medulloblastoma? Med Pediatr Oncol 36: 644–648.PubMedGoogle Scholar
  47. Hilden, J.M., Meerbaum, S., Burger, P., Finlay, J., Janss, A., Scheithauer, B.W., Walter, A.W., Rorke, L.B., and Biegel, J.A. 2004. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 22: 2877–2884.PubMedGoogle Scholar
  48. Hiyama, K., and Hiyama, E. 2002. [Telomere and telomerase in lung cancer]. Nippon Rinsho 60 Suppl 5: 737–742.PubMedGoogle Scholar
  49. Hoot, A.C., Russo, P., Judkins, A.R., Perlman, E.J., and Biegel, J.A. 2004. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol 28: 1485–1491.PubMedGoogle Scholar
  50. Hosoi, H., Iehara, T., Tsuchiya, K., Misawa, A., Miyaji, M., Yagyu, S., Koizumi, M., Nishimura, T., Tokiwa, K., Iwai, N., et al. 2007. Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse. J Pediatr Surg 42: E9–E12.PubMedGoogle Scholar
  51. Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., et al. 2007. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4): 799–805.Google Scholar
  52. Hulsebos, T.J., Plomp, A.S., Wolterman, R.A., Robanus-Maandag, E.C., Baas, F., and Wesseling, P. 2007. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet 80: 805–810.PubMedGoogle Scholar
  53. Igawa, M., Tanabe, T., Chodak, G.W., and Rukstalis, D.B. 1994. N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells. Prostate 24: 299–305.PubMedGoogle Scholar
  54. Isakoff, M.S., Sansam, C.G., Tamayo, P., Subramanian, A., Evans, J.A., Fillmore, C.M., Wang, X., Biegel, J.A., Pomeroy, S.L., Mesirov, J.P., et al. 2005. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 102: 17745–17750.PubMedGoogle Scholar
  55. Jaboin, J., Wild, J., Hamidi, H., Khanna, C., Kim, C.J., Robey, R., Bates, S.E., and Thiele, C.J. 2002. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 62: 6108–6115.PubMedGoogle Scholar
  56. Jang, T.J., Park, J.H., Cho, M.Y., and Kim, J.R. 2001. Chemically induced rat mammary tumor treated with tamoxifen showed decreased expression of cyclin D1, cyclin E, and p21(Cip1). Cancer Lett 170: 109–116.PubMedGoogle Scholar
  57. Kalpana, G.V., Marmon, S., Wang, W., Crabtree, G.R., and Goff, S.P. 1994. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5 [see comments]. Science 266: 2002–2006.PubMedGoogle Scholar
  58. Kato, H., Honma, R., Sanda, T., Fujiwara, T., Ito, E., Yanagisawa, Y., Imai, J., Okamoto, T., and Watanabe, S. 2007. Knock down of hSNF5/Ini1 causes cell cycle arrest and apoptosis in a p53-dependent manner. Biochem Biophys Res Commun 361: 580–585.PubMedGoogle Scholar
  59. Kent, A.L., Mahoney, D.H., Jr., Gresik, M.V., Steuber, C.P., and Fernbach, D.J. 1987. Malignant rhabdoid tumor of the extremity. Cancer 60: 1056–1059.PubMedGoogle Scholar
  60. Kirkwood, J. 2002. Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29: 18–26.PubMedGoogle Scholar
  61. Klochendler-Yeivin, A., Fiette, L., Barra, J., Muchardt, C., Babinet, C., and Yaniv, M. 2000. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep 1: 500–506.PubMedGoogle Scholar
  62. Kuwahara, Y., Hosoi, H., Osone, S., Kita, M., Iehara, T., Kuroda, H., and Sugimoto, T. 2004. Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. Clin Cancer Res 10: 5940–5948.PubMedGoogle Scholar
  63. Leggas, M., Stewart, C.F., Woo, M.H., Fouladi, M., Cheshire, P.J., Peterson, J.K., Friedman, H.S., Billups, C., and Houghton, P.J. 2002. Relation between irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 8: 3000–3007.PubMedGoogle Scholar
  64. Liang, J., and Slingerland, J.M. 2003. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2: 339–345.PubMedGoogle Scholar
  65. Liu, X., Lei, M., and Erikson, R.L. 2006. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26: 2093–2108.PubMedGoogle Scholar
  66. Lovat, P.E., Corazzari, M., Di Sano, F., Piacentini, M., and Redfern, C.P. 2005. The role of gangliosides in fenretinide-induced apoptosis of neuroblastoma. Cancer Lett 228: 105–110.PubMedGoogle Scholar
  67. Lovat, P.E., Corazzari, M., Goranov, B., Piacentini, M., and Redfern, C.P. 2004. Molecular mechanisms of fenretinide-induced apoptosis of neuroblastoma cells. Ann NY Acad Sci 1028: 81–89.PubMedGoogle Scholar
  68. Madigan, C.E., Armenian, S.H., Malogolowkin, M.H., and Mascarenhas, L. 2007. Extracranial malignant rhabdoid tumors in childhood: the Childrens Hospital Los Angeles experience. Cancer 110: 2061–2066.PubMedGoogle Scholar
  69. Mani, S., Wang, C., Wu, K., Francis, R., and Pestell, R. 2000. Cyclin-dependent kinase inhibitors: novel anticancer agents. Expert Opin Investig Drugs 9: 1849–1870.PubMedGoogle Scholar
  70. Martens, J.A., and Winston, F. 2003. Recent advances in understanding chromatin remodeling by Swi/Snf complexes. Curr Opin Genet Dev 13: 136–142.PubMedGoogle Scholar
  71. McInnes, C., Mezna, M., and Fischer, P.M. 2005. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 5: 181–197.PubMedGoogle Scholar
  72. Medjkane, S., Novikov, E., Versteege, I., and Delattre, O. 2004. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization. Cancer Res 64: 3406–3413.PubMedGoogle Scholar
  73. Mitchell, C., Jones, P.M., Kelsey, A., Vujanic, G.M., Marsden, B., Shannon, R., Gornall, P., Owens, C., Taylor, R., Imeson, J., et al. 2000. The treatment of Wilms’ tumour: results of the United Kingdom Children’s cancer study group (UKCCSG) second Wilms’ tumour study. Br J Cancer 83: 602–608.PubMedGoogle Scholar
  74. Moiseeva, O., Mallette, F.A., Mukhopadhyay, U.K., Moores, A., and Ferbeyre, G. 2006. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell 17: 1583–1592.PubMedGoogle Scholar
  75. Morozov, A., Lee, S.J., Zhang, Z.K., Cimica, V., Zagzag, D., and Kalpana, G.V. 2007. INI1 induces interferon signaling and spindle checkpoint in rhabdoid tumors. Clin Cancer Res 13: 4721–4730.PubMedGoogle Scholar
  76. Narlikar, G.J., Phelan, M.L., and Kingston, R.E. 2001. Generation and interconversion of multiple distinct nucleosomal states as a mechanism for catalyzing chromatin fluidity. Mol Cell 8: 1219–1230.PubMedGoogle Scholar
  77. Oruetxebarria, I., Venturini, F., Kekarainen, T., Houweling, A., Zuijderduijn, L.M., Mohd-Sarip, A., Vries, R.G., Hoeben, R.C., and Verrijzer, C.P. 2004. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem 279: 3807–3816.PubMedGoogle Scholar
  78. Ota, S., Crabbe, D.C., Tran, T.N., Triche, T.J., and Shimada, H. 1993. Malignant rhabdoid tumor. A study with two established cell lines. Cancer 71: 2862–2872.PubMedGoogle Scholar
  79. Packer, R.J., Biegel, J.A., Blaney, S., Finlay, J., Geyer, J.R., Heideman, R., Hilden, J., Janss, A.J., Kun, L., Vezina, G., et al. 2002. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol 24: 337–342.PubMedGoogle Scholar
  80. Pammer, J., Reinisch, C., Birner, P., Pogoda, K., Sturzl, M., and Tschachler, E. 2006. Interferon-alpha prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab Invest 86: 997–1007.PubMedGoogle Scholar
  81. Panigone, S., Debernardi, S., Taya, Y., Fontanella, E., Airoldi, R., and Delia, D. 2000. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide. Oncogene 19: 4035–4041.PubMedGoogle Scholar
  82. Pirkmaier, A., Yuen, K., Hendley, J., O’Connell, M.J., and Germain, D. 2003. Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide. Clin Cancer Res 9: 1877–1884.PubMedGoogle Scholar
  83. Pomeroy, S.L., Tamayo, P., Gaasenbeek, M., Sturla, L.M., Angelo, M., McLaughlin, M.E., Kim, J.Y., Goumnerova, L.C., Black, P.M., Lau, C., et al. 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436–442.PubMedGoogle Scholar
  84. Reddy, A.T. 2005. Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol 75: 309–313.PubMedGoogle Scholar
  85. Reincke, B.S., Rosson, G.B., Oswald, B.W., and Wright, C.F. 2003. INI1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells. J Cell Physiol 194: 303–313.PubMedGoogle Scholar
  86. Reynolds, C.P. 2004. Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 8 Suppl 5: 56–66.PubMedGoogle Scholar
  87. Reynolds, C.P., and Lemons, R.S. 2001. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 15: 867–910.PubMedGoogle Scholar
  88. Reynolds, C.P., Matthay, K.K., Villablanca, J.G., and Maurer, B.J. 2003. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197: 185–192.PubMedGoogle Scholar
  89. Roberts, C.W., Leroux, M.M., Fleming, M.D., and Orkin, S.H. 2002. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2: 415–425.PubMedGoogle Scholar
  90. Roper, M., Parmley, R.T., Crist, W.M., Kelly, D.R., Hyland, C.H., and Salter, M. 1981. Rhabdoid tumor of the kidney: complete remission induced by cis-platinum and adriamycin. Med Pediatr Oncol 9: 175–180.PubMedGoogle Scholar
  91. Schmidt, M., Fernandez de Mattos, S., van der Horst, A., Klompmaker, R., Kops, G.J., Lam, E.W., Burgering, B.M., and Medema, R.H. 2002. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 22: 7842–7852.PubMedGoogle Scholar
  92. Sevenet, N., Lellouch-Tubiana, A., Schofield, D., Hoang-Xuan, K., Gessler, M., Birnbaum, D., Jeanpierre, C., Jouvet, A., and Delattre, O. 1999. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype–phenotype correlations. Hum Mol Genet 8: 2359–2368.PubMedGoogle Scholar
  93. Smith, M.E., Cimica, V., Chinni, S., Challagulla, K., Mani, S., and Kalpana, G.V. 2008. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 14(2): 523–532.PubMedGoogle Scholar
  94. Soffer, S.Z., Kim, E., Huang, J., McCrudden, K., Yokoi, A., Moore, J.T., Manley, C., O’Toole, K., Middlesworth, W., Stolar, C., et al. 2002. Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. J Pediatr Surg 37: 528–532.PubMedGoogle Scholar
  95. Soria, J.C., Moon, C., Wang, L., Hittelman, W.N., Jang, S.J., Sun, S.Y., Lee, J.J., Liu, D., Kurie, J.M., Morice, R.C., et al. 2001. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 93: 1257–1263.PubMedGoogle Scholar
  96. Soria, J.C., Xu, X., Liu, D.D., Lee, J.J., Kurie, J., Morice, R.C., Khuri, F., Mao, L., Hong, W.K., and Lotan, R. 2003. Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. J Natl Cancer Inst 95: 165–168.PubMedGoogle Scholar
  97. Strother, D. 2005. Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther 5: 907–915.PubMedGoogle Scholar
  98. Sun, S.Y., Yue, P., Kelloff, G.J., Steele, V.E., Lippman, S.M., Hong, W.K., and Lotan, R. 2001. Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers Prev 10: 595–601.PubMedGoogle Scholar
  99. Sun, S.Y., Yue, P., and Lotan, R. 1999. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 55: 403–410.PubMedGoogle Scholar
  100. Takada, Y., and Aggarwal, B.B. 2004. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 279: 4750–4759.PubMedGoogle Scholar
  101. Tekautz, T.M., Fuller, C.E., Blaney, S., Fouladi, M., Broniscer, A., Merchant, T.E., Krasin, M., Dalton, J., Hale, G., Kun, L.E., et al. 2005. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 23: 1491–1499.PubMedGoogle Scholar
  102. Tomlinson, G.E., Breslow, N.E., Dome, J., Guthrie, K.A., Norkool, P., Li, S., Thomas, P.R., Perlman, E., Beckwith, J.B., D’Angio, G.J., et al. 2005. Rhabdoid tumor of the kidney in the National Wilms’ Tumor Study: age at diagnosis as a prognostic factor. J Clin Oncol 23: 7641–7645.PubMedGoogle Scholar
  103. Tsikitis, M., Zhang, Z., Edelman, W., Zagzag, D., and Kalpana, G.V. 2005. Genetic ablation of cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci USA 102: 12129–12134.PubMedGoogle Scholar
  104. Versteege, I., Sevenet, N., Lange, J., Rousseau-Merck, M.F., Ambros, P., Handgretinger, R., Aurias, A., and Delattre, O. 1998. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203–206.PubMedGoogle Scholar
  105. Vries, R.G., Bezrookove, V., Zuijderduijn, L.M., Kia, S.K., Houweling, A., Oruetxebarria, I., Raap, A.K., and Verrijzer, C.P. 2005. Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev 19: 665–670.PubMedGoogle Scholar
  106. Wagner, L., Hill, D.A., Fuller, C., Pedrosa, M., Bhakta, M., Perry, A., and Dome, J.S. 2002. Treatment of metastatic rhabdoid tumor of the kidney. J Pediatr Hematol Oncol 24: 385–388.PubMedGoogle Scholar
  107. Wall, L., Burke, F., Smyth, J.F., and Balkwill, F. 2003. The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecol Oncol 88: S149–S151.PubMedGoogle Scholar
  108. Wang, H., Charles, A.G., Frankel, A.J., and Cabot, M.C. 2003. Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. Urology 61: 1047–1052.PubMedGoogle Scholar
  109. Wang, W., Cote, J., Xue, Y., Zhou, S., Khavari, P.A., Biggar, S.R., Muchardt, C., Kalpana, G.V., Goff, S.P., Yaniv, M., et al. 1996. Purification and biochemical heterogeneity of the mammalian SWI–SNF complex. EMBO J 15: 5370–5382.PubMedGoogle Scholar
  110. Xin, H., Curry, J., Johnstone, R.W., Nickoloff, B.J., and Choubey, D. 2003. Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence. Oncogene 22: 4831–4840.PubMedGoogle Scholar
  111. Yamamoto, M., Suzuki, N., Hatakeyama, N., Mizue, N., Hori, T., Kuroiwa, Y., Hareyama, M., Oda, T., Kudoh, T., Nui, A., et al. 2006. Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and VDCy: a case report. J Pediatr Hematol Oncol 28: 286–289.PubMedGoogle Scholar
  112. Zanardi, S., Serrano, D., Argusti, A., Barile, M., Puntoni, M., and Decensi, A. 2006. Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer 13: 51–68.PubMedGoogle Scholar
  113. Zhang, Z.K., Davies, K.P., Allen, J., Zhu, L., Pestell, R.G., Zagzag, D., and Kalpana, G.V. 2002. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 22: 5975–5988.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Molecular Genetics and Albert Einstein College Cancer CenterAlbert Einstein College of Medicine of Yeshiva UniversityBronxUSA

Personalised recommendations